One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
Muthiah Vaduganathan, MD, MPH,a, * Brian L. Claggett, P HD, a, * Pardeep Jhund, MD, PHD, b Rudolf A. de Boer, MD,c Adrian F. Hernandez, MD,d Silvio E. Inzucchi, MD,e Mikhail N. Kosiborod, MD,f Carolyn S.P. Lam, MD, g Felipe Martinez, MD, h Sanjiv J. Shah, MD, i Akshay S. Desai, MD, a Daniel Lindholm, MD, P HD, j Magnus Petersson, MD, PHD, j Anna Maria Langkilde, MD, j John J.V. McMurray, b Scott D. Solomon, MD
doi : 10.1016/j.jacc.2022.08.745
Volume 80, Issue 19, 8 November 2022, Pages 1775-1784
Recent guidelines support consideration of sodium-glucose cotransporter-2 inhibitors in the long-term management of heart failure (HF) with mildly reduced or preserved ejection fraction. Patients and clinicians may be interested in the expected lifetime benefits of sodium-glucose cotransporter-2 inhibitors in this population.
Implementing Sodium-Glucose Cotransporter-2 Inhibitor Therapy for Heart Failure: What Is the Message to DELIVER?
Michael E. Nassif, MD,a James L. Januzzi, J R , MD
doi : 10.1016/j.jacc.2022.09.008
Volume 80, Issue 19, 8 November 2022, Pages 1785-1787
Risk Factors for In-Hospital Cardiac Arrest in Patients With ST-Segment Elevation Myocardial Infarction
Wei Gong, MD, PHD, a,b,c, * Yan Yan, MD, a,b,c, * Xiao Wang, MD,a,b,c Wen Zheng, MD,a,b,c Sidney C. Smith, J R , MD,d Gregg C. Fonarow, MD, e Louise Morgan, MSN,f Jing Liu, MD, PHD, g Dong Zhao, MD, PH D, g Changsheng Ma, MD,b,c,h Yaling Han, MD, PHD, i Gilles Montalescot, MD, PH D, j Shaoping Nie, MD, PHD, a,b,c on behalf of the CCC-ACS Investigators
doi : 10.1016/j.jacc.2022.08.797
Volume 80, Issue 19, 8 November 2022, Pages 1788-1798
In-hospital cardiac arrest (IHCA) is one of the most deleterious complications of ST-segment elevation myocardial infarction (STEMI).
Contemporary Approaches to Reducing Morbidity and Mortality in Patients With Acute Coronary Syndromes
Graham Nichol, MD, MPH,a,b,y Amanda West, MD, MPH
doi : 10.1016/j.jacc.2022.09.009
Volume 80, Issue 19, 8 November 2022, Pages 1799-1801
Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction
Barbara E. Stähli, MD, MPH, MBA, a, * Roland Klingenberg, MD, b, * Dik Heg, P HD, c Mattia Branca, PH D, c Robert Manka, MD, a,d Ioannis Kapos, MD,a Oliver Müggler, MD, a Andrea Denegri, MD, a Rahel Kesterke, PHD, a Florence Berger, PH D, a Julia Stehli, MD,a Alessandro Candreva, MD,a Arnold von Eckardstein, MD, e David Carballo, MD,f Christian Hamm, MD, b Ulf Landmesser, MD, g François Mach, MD,f Tiziano Moccetti, MD, h Christian Jung, MD,i Malte Kelm, MD, i Thomas Münzel, MD, j Giovanni Pedrazzini, MD,h Lorenz Räber, MD, P HD, k Stephan Windecker, MD,k Christian Templin, MD, PHD, a Christian M. Matter, MD, a Thomas F. Lüscher, MD,l,m,y Frank Ruschitzka, MD
doi : 10.1016/j.jacc.2022.08.747
Volume 80, Issue 19, 8 November 2022, Pages 1802-1814
Early inflammation following acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) affects myocardial infarct (MI) size and left ventricular remodeling. The mammalian target of rapamycin (mTOR) is involved in the enhanced inflammatory response and its inhibition has exerted beneficial effects on MI size in preclinical models of acute MI.
Inhibition of the Mechanistic Target of Rapamycin in Acute Myocardial Infarction∗
Jean-Claude Tardif, MD, Eric Thorin, PHD
doi : 10.1016/j.jacc.2022.08.796
Volume 80, Issue 19, 8 November 2022, Pages 1815-1817
Air Pollution and Coronary Vasomotor Disorders in Patients With Myocardial Ischemia and Unobstructed Coronary Arteries
Massimiliano Camilli, MD,a,b, * Michele Russo, MD, P HD, a, * Riccardo Rinaldi, MD, a Andrea Caffè, MD,a Giulia La Vecchia, MD,a Alice Bonanni, BSC , PH D, a Giulia Iannaccone, MD, a Mattia Basile, MD,a Rocco Vergallo, MD, PH D, b Cristina Aurigemma, MD, PHD, b Carlo Trani, MD, a,b Giampaolo Niccoli, MD, PH D, c Filippo Crea, MD, a,b,y Rocco A. Montone, MD, PHD
doi : 10.1016/j.jacc.2022.08.744
Volume 80, Issue 19, 8 November 2022, Pages 1818-1828
Coronary vasomotor abnormalities are important causes of myocardial ischemia in patients with nonobstructive coronary artery disease (NOCAD). However, the role of air pollution in determining coronary vasomotor disorders has never been investigated.
The Perils of Anthropogenic Air Pollution: When All Roads Led to Rome
Sanjay Rajagopalan, MD, a Jagat Narula, MD
doi : 10.1016/j.jacc.2022.09.015
Volume 80, Issue 19, 8 November 2022, Pages 1829-1832
Coronary Artery Bypass Surgery Without Saphenous Vein Grafting: JACC Review Topic of the Week
Alistair Royse, MBBS, MD, a,b, * Justin Ren, BMEDS C,a, * Colin Royse, MBBS, MD,a,b,c David H. Tian, MD, PHD, d Stephen Fremes, MD, MS C, e Mario Gaudino, MD, PHD, f Umberto Benedetto, MD, P HD, g Y. Joseph Woo, MD,h Andrew B. Goldstone, MD, PH D, i Piroze Davierwala, MBBS, P HD, e,j Michael Borger, MD, PHD, j Michael Vallely, MBBS, PHD, k Christopher M. Reid, MSC , BA, PHD, l Rodolfo Rocha, MD, P HD, e David Glineur, MD, PH D, m,n Juan Grau, MD, P HD, m Richard Shaw, MD,o Hugh Paterson, MBBS, p Doa El-Ansary, BAPPSC (P HTY), PH D, a,q Stuart Boggett, BS CI, MC-BM EDS C,a Nilesh Srivastav, MBBS, a Zulfayandi Pawanis, MBBS, MB IOMEDS CI,r David Canty, MBBS, PHD, a Rinaldo Bellomo, MD, PH D
doi : 10.1016/j.jacc.2022.08.795
Volume 80, Issue 19, 8 November 2022, Pages 1833-1843
Approximately 95% of patients of any age undergoing contemporary, coronary bypass surgery will receive at least 1Â saphenous vein graft (SVG). It is recognized that SVG will develop progressive and accelerated atherosclerosis, resulting in a stenosis, and in occlusion that occurs in 50% by 10 years postoperatively.
ACC Advocacy: Engage, Influence, Advocate
Edward T.A. Fry, MD, FACC, President, American College of Cardiology Samuel O. Jones IV, MD, MPH, FACC, Chair, Health Affairs Committee Nick Morse, MBA, ACC Division Vice President, Advocacy
doi : 10.1016/j.jacc.2022.09.022
Volume 80, Issue 19, 8 November 2022, Pages 1844-1847
Paradigm Shift to Address Cardiovascular Health at Every Stage
Valentin Fuster, MD, P HD, Editor-in-Chief, Journal of the American College of Cardiology, Justine Varieur Turco, MA, Divisional Vice President, American College of Cardiology
doi : 10.1016/j.jacc.2022.09.017
Volume 80, Issue 19, 8 November 2022, Pages 1848-1850
Strategies to Diversify the Medical Student Training Pipeline Into Cardiology
Samip Sheth, MB, a Adriana C. Mares, MS, b Gurleen Kaur, MD
doi : 10.1016/j.jacc.2022.08.788
Volume 80, Issue 19, 8 November 2022, Pages 1851-1854
RESPONSE: Innovative Mentorship Models Integral for Diversifying the CV Pipeline
Melvin R. Echols, MD
doi : 10.1016/j.jacc.2022.08.798
Volume 80, Issue 19, 8 November 2022, Page 1854
Time-Varying Cardiovascular Effects of Finerenone in Diabetic Kidney Disease: Insights From FIDELIO-DKD and FIGARO-DKD Trials
Sadeer Al-Kindi, MD Issam Motairek, MD Scott Janus, MD Salil Deo, MD Mahboob Rahman, MD Ian J. Neeland, MD Sanjay Rajagopalan, MD
doi : 10.1016/j.jacc.2022.08.791
Volume 80, Issue 19, 8 November 2022, Pages 1855-1856
The War for the Best Therapy in Coronary Artery Disease Is Far From Being Won
Nicola Gaibazzi, MD, PhD Alberto Foà , MD Luca Bergamaschi, MD Domenico Tuttolomondo, MD Carmine Pizzi, MD
doi : 10.1016/j.jacc.2022.08.792
Volume 80, Issue 19, 8 November 2022, Page e167
Limitations of Myocardial Perfusion Imaging vs Exercise Testing for Mortality Outcome Prediction
*Wade H. Martin III, MD
doi : 10.1016/j.jacc.2022.08.794
Volume 80, Issue 19, 8 November 2022, Page e169
Reply: Reconciling the Use of Myocardial Ischemia Testing for Selecting Patients for Coronary Revascularization
Alan Rozanski, MD Robert J.H. Miller, MD Donghee Han, MD Daniel S. Berman, MD
doi : 10.1016/j.jacc.2022.08.793
Volume 80, Issue 19, 8 November 2022, Pages e171-e172
